설사형 과민성 장 증후군 남성 환자에게 사용되는 ramosetron 의 경제성 평가Economic Evaluation of Ramosetron in Male Patients with Diarrhea-predominant Irritable Bowel Syndrome in Korea
- Other Titles
- Economic Evaluation of Ramosetron in Male Patients with Diarrhea-predominant Irritable Bowel Syndrome in Korea
- Authors
- 손현순; 이태진; 김선
- Issue Date
- Dec-2010
- Publisher
- 한국임상약학회
- Keywords
- cost-utility; irritable bowel syndrome; ramosetron; trimebutine; loperamide
- Citation
- 한국임상약학회지, v.20, no.3, pp 268 - 277
- Pages
- 10
- Journal Title
- 한국임상약학회지
- Volume
- 20
- Number
- 3
- Start Page
- 268
- End Page
- 277
- URI
- https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/52418
- ISSN
- 1226-6051
- Abstract
- This study was conducted to analyze the cost-utility of ramosetron monotherapy, trimebutine monotherapy and trimebutine+loperamide combination therapy in male diarrhea-predominant patients with irritable bowel syndrome (IBS) in Korean healthcare setting. We constructed a decision-analytical model to estimate both total costs for each state of health and outcomes such as IBS-symptoms improvement for 3 and 6 months time horizon. Base analysis found that for ramosetron treatment with the price of KW910 for 5 μg tablet, incremental cost effectiveness ratios (ICERs, cost per quality-adjusted life day) were KW85,000 and KW62,000 for 3 months and 6 months, respectively, compared with trimebutine.
But ramosetron was a dominant strategy when compared with trimebutine+loperamide for both 3 months and 6 months. Sensitivity analyses showed robust results for drug acquisition costs till ramosetron price of KW950/tablet. In conclusion, ramosetron was a cost-effective regimen compared with trimebutine or trimebutine+loperamide from the societal perspective.
- Files in This Item
-
Go to Link
- Appears in
Collections - 약학대학 > 약학부 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.